


BI 703704

Cat. No.:	HY-117962A
Molecular Formula:	C ₃₂ H ₃₇ N ₃ O ₄ S
Molecular Weight:	559.72
Target:	Guanylate Cyclase
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BI 703704 is a potent soluble guanylate cyclase (sGC) activator. BI 703704 inhibits the progression of diabetic nephropathy in the ZSF1 rat ^[1] .								
In Vivo	<p>BI 703704 (0.3-10 mg/kg; food intake; daily for 15 weeks) results in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content^[1].</p> <p>BI 703704 is effective in elevating renal cGMP levels in a dose-dependent manner and in slowing the progression of diabetic nephropathy in an oxidative stress milieu^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Fifty-eight male ZSF1 rats (12-13 weeks)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.3, 1, 3, or 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Food intake; daily for 15 weeks</td> </tr> <tr> <td>Result:</td> <td>Resulted in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content.</td> </tr> </table>	Animal Model:	Fifty-eight male ZSF1 rats (12-13 weeks) ^[1]	Dosage:	0.3, 1, 3, or 10 mg/kg	Administration:	Food intake; daily for 15 weeks	Result:	Resulted in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content.
Animal Model:	Fifty-eight male ZSF1 rats (12-13 weeks) ^[1]								
Dosage:	0.3, 1, 3, or 10 mg/kg								
Administration:	Food intake; daily for 15 weeks								
Result:	Resulted in dose-dependent decreases in urinary protein excretion (UPE), and a dose-dependent increase in renal cGMP content.								

REFERENCES

[1]. Boustany-Kari CM, et al. A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat. J Pharmacol Exp Ther. 2016 Mar;356(3):712-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA